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Abstract
Patient reported outcomes provide the patient's perspective on the effectiveness of treatment. The
draft Food and Drug Administration guidance on patient reported outcomes for labeling and
promotional claims raises a number of method and measurement issues that require further
clarification, including methods of determining responsiveness and minimal important differences.
For clinical trials, instruments need to be based on a clear conceptual framework, have evidence
supporting content validity and acceptable psychometric qualities. The measures must also have
evidence documenting responsiveness and interpretation guidelines (i.e., minimal important
difference) to be most useful as effectiveness endpoints in clinical trials. The recommended
approach is to estimate the minimal important difference based on several anchor-based methods,
with relevant clinical or patient-based indicators, and to examine various distribution-based
estimates (i.e., effect size, standardized response mean, standard error of measurement) as
supportive information, and then to triangulate on a single value or small range of values for the
MID. Confidence in a specific MID value evolves over time and is confirmed by additional research
evidence, including clinical trial experience. The MID may vary by population and context, and no
one MID will be valid for all study applications involving a PRO instrument. Responsiveness and MID
must be demonstrated and documented for the particular study population, and these
measurement characteristics are needed for PRO labeling and promotional claims.
Introduction
Patient reported outcomes (PROs) provide the patient's
perspective on the effectiveness of treatment, and for
many diseases the patient is really the only source of
health outcome endpoint data [1-3]. The draft FDA guid-
ance on PROs for labeling and promotional claims raises
a number of method and measurement issues that require
further clarification [4]. For clinical trials evaluating new
pharmaceuticals, PRO instruments need to be based on a
clear conceptual framework, have evidence supporting
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content validity (i.e., the instrument content reflects the
key characteristics of the construct from the patient's per-
spective), and must have demonstrated acceptable psy-
chometric qualities (e.g., reliability, validity) [1,2]. The
PRO measures must also have evidence documenting
responsiveness or sensitivity to changes in clinical status
to be most useful as effectiveness endpoints in clinical tri-
als. Without evidence that the PRO can detect meaningful
changes in health status, using the PRO in a clinical trial
may be risky, because clinically meaningful effects may go
undetected. Responsiveness is an aspect of construct valid-
ity and is determined by evaluating the relationship
between changes in clinical and other endpoints and
changes in the PRO scores over time, or based on the
application of a treatment of known and demonstrated
efficacy, in either observational studies or in clinical trials
[2,5,6].
Demonstrating responsiveness is necessary, but addi-
tional information is needed to determine the minimally
important difference (MID) for a PRO measure. Respon-
siveness represents the instrument's ability to detect
changes in health status while MID is used to interpret
whether the observed change is important from the
patient's or clinician's perspective. Increasingly, in health
outcomes research the MID is based primarily on the
patient's perspective with the clinician's viewpoint serving
to confirm the findings on MID. Responsiveness and MID
vary by population and contextual characteristics, and
there is no single MID value for a PRO instrument across
all applications and patient samples. Once that range in
MIDs is determined, one can decided which particular
value to use as a basis for sample size calculation.
The MID has been defined as the smallest change in a PRO
measure that is perceived by patients as beneficial or that
would result in a change in treatment [5,7]. There are a
number of anchor-based and distribution-based methods
that have been used to determine the MID for PRO meas-
ures [7-9]. The anchor-based methods require an external
patient-based or clinical criteria to inform as to changes in
PRO scores that are meaningful. The distribution-based
methods reflect one or several statistical indices of change.
However, the current situation for determining the MID is
fluid, but there is an evolving consensus as to the recom-
mended, best practice methods for determining the MID
[7].
The recommended approach is to estimate the MID based
on several anchor-based methods, with relevant clinical or
patient-based indicators, and to examine various distribu-
tion-based estimates (i.e., effect size, standardized
response mean, standard error of measurement) as sup-
portive information, and then to triangulate on a single
value or small range of values for the MID. Confidence in
a specific MID value evolves over time and is confirmed
by additional research evidence, including clinical trial
experience. It must be recognized and accepted that
aspects of PRO assessment include some measurement
error and that no PRO measure is error free and should
not be expected to be so in order to be used in clinical tri-
als. There does however need to be evidence that the psy-
chometric characteristics of the PRO instrument are such
that there is confidence that changes in scores over time
with the application of treatments with some efficacy can
be detected [10] and that the measurement error (or
noise) is not so large that it is problematic to observe
meaningful changes in patients' health status.
Assessing the responsiveness of PRO 
instruments
Longitudinal studies are needed to determine whether a
PRO instrument is responsive to changes or differences in
health status. These studies may be randomized clinical
trials comparing treatments of known efficacy or observa-
tional studies where patients are treated with usual medi-
cal care and followed over relevant periods of time. To
assess responsiveness, some criterion is needed to identify
whether patients have changed (either improved or wors-
ened) over time. These criteria, or anchors, may be clinical
endpoints (i.e., laboratory measures, physiological meas-
ures, clinician ratings), patient-rated global improvement
or other PROs with established responsiveness, or some
combination of clinical and patient-based outcomes. The
anchor-based approaches use an external indicator, either
clinical or patient-based, to assign subjects into several
groupings reflecting no change, small positive changes,
large positive changes, small negative changes, or large
negative changes in clinical or health status. It is highly
recommended to use multiple independent anchors and
to examine and confirm responsiveness across multiple
samples.
Selecting anchors should be based on criteria of relevance
for the disease indication, clinical acceptance and validity,
and evidence that the anchors have some relationship
with the PRO measure. It is recommended that research-
ers determine the strength of the association of the anchor
measure with the PRO. An anchor that has a very low or
no correlation with the PRO instrument may provide mis-
leading information in determining whether significant
change has occurred. There also needs to be an under-
standing of the trajectory of health outcomes in the target
disease to evaluate responsiveness. For example, do most
patients improve over time with treatment, as with sea-
sonal allergic rhinitis or, as in many chronic diseases (e.g.,
COPD, arthritis, etc.) is the expected trajectory one of
maintenance of health status versus varying levels of dete-
rioration in health status over time, even with treatment?Health and Quality of Life Outcomes 2006, 4:70 http://www.hqlo.com/content/4/1/70
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Once groups of patients are identified as improving, wors-
ening or remaining stable based on several relevant exter-
nal anchors, several types of data analysis and indicators
can be used to examine responsiveness. First, analysis of
variance or covariance procedures can be performed com-
paring differences in mean baseline to endpoint changes
in the PRO scores across the meaningful change groups
(i.e., stable versus small improvement, stable versus mod-
erate improvement, etc.). Second, responsiveness to
change is frequently evaluated using different indicators
[6,10], such as the effect size (ES) [11], standardized
response mean (SRM) [12], and the responsiveness statis-
tic (RS) [5]. For these three indices, the numerator is the
mean baseline to endpoint change and the denominators
are the standard deviation (SD) at baseline (ES), the SD of
change for the group (SRM), or the SD of change in
patients that remain stable over time (RS). For the ES,
Cohen [13] provided guidance on interpretation of the
magnitude, where a 0.20 ES is considered a small change,
0.50 is viewed a moderate change, and 0.80 is viewed as a
large change.
Some researchers have suggested that the 1/2 standard
deviation rule [14] or that the standard error of measure-
ment (SEM) [15,16] may represent the MID for PRO
instruments. While this magnitude of change is certainly
clinically significant and important, since in the case of
the 1/2 SD this represents a moderate effect size [13], it
may not be the smallest nonignorable difference. These
differences in PRO scores are just too large to be consid-
ered minimally important. While these different distribu-
tion-based indicators demonstrate that change has
occurred and provide some insight as to whether the
change (responsiveness) is small or large, the indices do
not necessarily inform as to whether the observed change
in MID. To determine MID, it is necessary to get informa-
tion as to whether the observed change in important from
the patient's or clinician's perspective [17]. Based on these
methods, MIDs can be in the range of 0.20 to 0.30 ES (or
SD units).
Determining the MID for PRO instruments
For interpreting differences or changes in PRO instru-
ments, information needs to be provided as to whether
the changes seen in the scores are important from either
the patient's or clinician's perspective. The clinical mean-
ingfulness of the observed change is based on that change
being perceived as minimally important and that would
be perceived as beneficial from the patient's viewpoint. It
is recommended that the patient's perspective be given the
most weight, since these are PROs, although the clini-
cian's perspective is considered important as well. The
MID is determined based on multiple anchors, that is the
same external criteria used to evaluate responsiveness of
the PRO measure. However, there are differences in how
these data are used and compared to determine MID.
Since the focus is on determining the MID, it is necessary
to identify the smallest difference or change that is impor-
tant to the patient.
In many cases, global assessments of change in health or
clinical status are used to categorize patients into groups
that reflect, based on their own reports, different amounts
of change in the construct of interest. For example, based
on the Overall Treatment Effect (OTE) scale [18], patients
can be assigned into groups representing no change (i.e.,
remaining stable), small improvements, moderate
improvements or large improvements, and small amount
of worsening, moderate worsening, or large amounts of
worsening. The MID is viewed as the observed change
seen in the small improvement group, if this change is
larger than that seen in the stable group. If is some varia-
tion observed among the stable group, the MID may be
based on the difference in mean baseline to endpoint
change scores between the stable group and the small
improvement (or worsening) group. Note that there is evi-
dence that there is asymmetry in worsening and improve-
ment in PROs depending on the specific disease [19,20].
Equally, clinician global assessments of change in clinical
status or evaluations of clinical severity, clinical response
criteria (i.e., ACR response criteria) or other indicators can
be used to determine MID. For these clinical anchors, it
will be necessary to identify, based on previous research or
clinical consensus, what a small and clinically meaningful
effect may be, based on these measures. For example, in
rheumatoid arthritis, the differences between groups of
stable patients and those experiencing a 20% ACR
response can be used to determine the MID of a PRO
score. If multiple anchors are used, there will be several
different estimates of MID derived corresponding to these
different anchors, and the result will be a range of MID
estimates for the targeted PRO instrument.
Finally, the application of multiple methods to determine
the MID for a PRO instrument in a specific patient popu-
lation will result in a range of values for the MID. This is
the essence of triangulation, that is, examining multiple
values from different approaches and hopefully converg-
ing on a small range of values (or one single value). It is
recommended that the different MID estimates be first
graphed to visually depict the range of estimates. To iden-
tify a single MID value (or narrow range of MID values),
it is recommended that the anchor-based estimates be
assigned the most weight and experience from clinical tri-
als be used to further support and perhaps further narrow
the range of values. Care must be taken in selecting the
most appropriate anchors, as measurement error can be
magnified if the anchors are not measured reliably. Inter-
pretation of the MID from different anchors should also
take into account the proximity of the anchor to the targetHealth and Quality of Life Outcomes 2006, 4:70 http://www.hqlo.com/content/4/1/70
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PRO measure, that is, assign more importance to MIDs
generated from more closely linked concepts. A systematic
consensus process involving several clinicians and health
outcome researchers is recommended and can be com-
pleted, based on Delphi methods, to arrive at a single MID
value, or at least a narrower range of values. There is no
consensus as to how much data are needed as supportive
evidence for the MID of a PRO instrument. Clearly, the
more data and evidence the better, but a single, generaliz-
able study with multiple patient-based and clinical
anchors may be sufficient.
As with other aspects of construct validity, responsiveness
and the MID value are confirmed based on accumulating
evidence from multiple studies and, with additional data,
we can be more confident in the MID value. A single MID
cannot be assumed to be appropriate for all applications
and across all patient populations; it is unlikely that this
will be the case. For example, the MID derived for an
asthma-specific quality of life measure in mild to moder-
ate asthma patients may not be generalizable to clinical
trials comparing an add-on treatment for patients with
moderate to severe asthma [21]. Finally, it may not always
be feasible or practical to identify anchors for all PRO
assessments, in such cases, distribution-based approaches
to calculating the MID can still provide some guidance for
decision-making. Until further evidence is obtained
regarding the relative utility and veracity of competing
approaches for estimating an MID, it is likely that the opti-
mal approach will be study-specific.
Conclusion
For PRO endpoint data to be accepted as evidence of treat-
ment effectiveness, there must be evidence documenting
the instrument's conceptual framework, content validity,
and psychometric qualities, including reliability, validity
and responsiveness. For responsiveness, it is necessary to
demonstrate that the PRO scores are sensitive to actual
changes in clinical or health status. While demonstrating
responsiveness is a key component to establishing an
instrument's construct validity, it is also important to
determine the MID to assist in interpreting statistical sig-
nificant PRO results in clinical trials. The MID may vary by
population and context, and no one MID will be valid for
all study applications involving a PRO instrument.
Responsiveness and MID must be demonstrated and doc-
umented for the particular study population, and these
measurement characteristics are needed for PRO labeling
and promotional claims.
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